Interferon beta-1a Completed Phase 3 Trials for Relapsing Remitting Multiple Sclerosis (RRMS) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00099502BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients
NCT00292266A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
NCT00441103A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
NCT00530348Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One
NCT00548405Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
NCT00930553An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab
NCT00428584RNF and Betaseron® Tolerability Study
NCT00211887Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
NCT01064401Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis